What is Bicara Therapeutics's EBITDA?

Bicara Therapeutics (BCAX) reported EBITDA of -$60.2M in Q1 2026.

How has Bicara Therapeutics's EBITDA changed year-over-year?

Bicara Therapeutics's EBITDA decreased by 44.1% year-over-year, from -$41.77M to -$60.2M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Bicara Therapeutics BCAX EBITDA

EBITDA at other companies

ArriVent BioPharma, Inc.AVBP

-$46.67M+30.9%

ImmunomeIMNM

-$58.73M-33.4%

Arcus BiosciencesRCUS

-$132M-10.9%

Syndax PharmaceuticalsSNDX

-$30.2M+63.9%

Eli LillyLLY

——

AmgenAMGN

——

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.64B+81.4%

Enterprise value$1.32B+288%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Calculated from Bicara Therapeutics’s reported figures.

−$60.2Mebit+

$44.0KDepreciation Depletion & Amortization

=-$60.2M

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's EBITDA?: Bicara Therapeutics (BCAX) reported EBITDA of -$60.2M in Q1 2026.
How has Bicara Therapeutics's EBITDA changed year-over-year?: Bicara Therapeutics's EBITDA decreased by 44.1% year-over-year, from -$41.77M to -$60.2M.
What does EBITDA mean?: Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.